SEC Form SC 13G/A filed by Singular Genomics Systems Inc. (Amendment)

2/12/24 5:31:00 PM ET

$OMIC

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $OMIC alert in real time by email

SC 13G/A 1 e619251_sc13ga-sgs.htm

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 3)*

Singular Genomics Systems, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

82933R100

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

(Page 1 of 11 Pages)

----------

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.

82933R100

13G

Page 2 of 11

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Mgmt, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐

(b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

0.00%

12.

TYPE OF REPORTING PERSON*

CUSIP No.

82933R100

13G

Page 3 of 11

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Mgmt IV, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐

(b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

7,484,871 (1)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

7,484,871 (1)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,484,871 (1)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

6.79%

12.

TYPE OF REPORTING PERSON*

_________________

(1) Comprised of an aggregate of (i) 4,984,871 shares of Common Stock and (ii) 2,500,000 shares of Common Stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock, which are held by Deerfield Private Design Fund IV, L.P., of which Deerfield Mgmt IV, L.P. is the general partner. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 4.9% of the total number of shares of Common Stock then outstanding (the “Ownership Cap”). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of Common Stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

CUSIP No.

82933R100

13G

Page 4 of 11

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Partners, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐

(b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

0.00%

12.

TYPE OF REPORTING PERSON*

CUSIP No.

82933R100

13G

Page 5 of 11

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Private Design Fund IV, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐

(b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

7,484,871 (2)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

7,484,871 (2)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,484,871 (2)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

6.79%

12.

TYPE OF REPORTING PERSON*

_________________

(2) Comprised of an aggregate of (i) 4,984,871 shares of Common Stock and (ii) 2,500,000 shares of common stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 4.9% of the total number of shares of Common Stock then outstanding (the “Ownership Cap”). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of Common Stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

CUSIP No.

82933R100

13G

Page 6 of 11

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Management Company, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐

(b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

7,514,871 (3)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

7,514,871 (3)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,514,871 (3)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

6.83%

12.

TYPE OF REPORTING PERSON*

__________________

(3) Comprised of (i) an aggregate of 4,984,871 shares of Common Stock held by Deerfield Private Design Fund IV L.P., of which Deerfield Management Company, L.P. is the investment advisor, (ii) 2,500,000 shares of Common Stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock, which are held by Deerfield Private Design Fund IV, L.P. of which Deerfield Management Company, L.P. is the investment manager and (iii) 30,000 shares of Common Stock underlying stock options granted to Andrew ElBardissi, an employee of Deerfield Management Company, L.P., which are held for the benefit, and at the direction, of Deerfield Management Company, L.P. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 4.9% of the total number of shares of Common Stock then outstanding (the “Ownership Cap”). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of Common Stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

CUSIP No.

82933R100

13G

Page 7 of 11

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

James E. Flynn

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐

(b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

7,514,871 (4)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

7,514,871 (4)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,514,871 (4)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

6.83%

12.

TYPE OF REPORTING PERSON*

__________________

(4) Comprised of (i) an aggregate of 4,984,871 shares of Common Stock held by Deerfield Private Design Fund IV L.P., (ii) 2,500,000 shares of common stock issuable upon conversion of 2,500 shares of Series A Common Stock Equivalent Convertible Preferred Stock, which are held by Deerfield Private Design Fund IV L.P. and (iii) 30,000 shares of Common Stock underlying stock options granted to Andrew ElBardissi, an employee of Deerfield Management Company, L.P., which are held for the benefit, and at the direction, of Deerfield Management Company, L.P. The terms of the Series A Common Stock Equivalent Convertible Preferred Stock restrict the conversion of such shares to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 4.9% of the total number of shares of Common Stock then outstanding (the “Ownership Cap”). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of Common Stock issuable upon conversion of Series A Common Stock Equivalent Convertible Preferred Stock to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

CUSIP No.

82933R100

13G

Page 8 of 11

Item 1(a).	Name of Issuer:

	Singular Genomics Systems, Inc.

Item 1(b).	Address of Issuer's Principal Executive Offices:

	3010 Science Park Road, San Diego, CA 92121

Item 2(a).	Name of Person Filing:

	James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P.

Item 2(b).	Address of Principal Business Office, or if None, Residence:

	James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

Item 2(c).	Citizenship:

	Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P. - Delaware limited partnerships; James E. Flynn – United States citizen

Item 2(d).	Title of Class of Securities:

	Common Stock

Item 2(e).	CUSIP Number:

	82933R100

Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

(a)	☐	Broker or dealer registered under Section 15 of the Exchange Act.

(b)	☐	Bank as defined in Section 3(a)(6) of the Exchange Act.

(c)	☐	Insurance company as defined in Section 3(a)(19) of the Exchange Act.

(d)	☐	Investment company registered under Section 8 of the Investment Company Act.

(e)	☐	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);


(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

CUSIP No.

82933R100

13G

Page 9 of 11


(j)	☐	A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

Item 4.	Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned**:

	Deerfield Mgmt, L.P. - 0 shares Deerfield Mgmt IV, L.P. – 7,484,871 shares Deerfield Management Company, L.P. - 7,514,871 shares Deerfield Partners, L.P. - 0 shares Deerfield Private Design Fund IV, L.P. – 7,484,871 shares James E. Flynn – 7,514,871 shares

(b)	Percent of class**:

	Deerfield Mgmt, L.P. – 0.00% Deerfield Mgmt IV, L.P. – 6.79% Deerfield Management Company, L.P. – 6.83% Deerfield Partners, L.P. - 0.00% Deerfield Private Design Fund IV, L.P. – 6.79% James E. Flynn – 6.83%

(c)	Number of shares as to which such person has**:

	(i)	Sole power to vote or to direct the vote:	All Reporting Persons - 0

	(ii)	Shared power to vote or to direct the vote:	Deerfield Mgmt, L.P. - 0 Deerfield Mgmt IV, L.P. – 7,484,871 Deerfield Management Company, L.P. - 7,514,871 Deerfield Partners, L.P. - 0 Deerfield Private Design Fund IV, L.P. – 7,484,871 James E. Flynn – 7,514,871

	(iii)	Sole power to dispose or to direct the disposition of:	All Reporting Persons - 0

	(iv)	Shared power to dispose or to direct the disposition of:	Deerfield Mgmt, L.P. - 0 Deerfield Mgmt IV, L.P. – 7,484,871 Deerfield Management Company, L.P. - 7,514,871 Deerfield Partners, L.P. - 0 Deerfield Private Design Fund IV, L.P. – 7,484,871 James E. Flynn – 7,514,871

**See footnotes on cover pages which are incorporated by reference herein.

CUSIP No.

82933R100

13G

Page 10 of 11

Item 5.	Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☒.

	This box is being checked solely with respect to Deerfield Mgmt, L.P. and Deerfield Partners, L.P.

Item 6.	Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

	N/A

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

	N/A

Item 8.	Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

	See Exhibit B

Item 9.	Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

	N/A

Item 10.	Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

CUSIP No.

82933R100

13G

Page 11 of 11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MGMT IV, L.P.

By: J.E. Flynn Capital IV, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PRIVATE DESIGN FUND IV, L.P.

By: Deerfield Mgmt IV, L.P., General Partner

By: J.E. Flynn Capital IV, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Date: February 12, 2024

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney (1).

(1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

Exhibit A

Joint Filing Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Singular Genomics Systems, Inc. shall be filed on behalf of the undersigned.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MGMT IV, L.P.

By: J.E. Flynn Capital IV, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PRIVATE DESIGN FUND IV, L.P.

By: Deerfield Mgmt IV, L.P., General Partner

By: J.E. Flynn Capital IV, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Exhibit B

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

Get the next $OMIC alert in real time by email

Date	Price Target	Rating	Analyst
8/17/2022	$10.00 → $4.50	Buy → Neutral	UBS
8/10/2022	$3.50	Buy → Neutral	Goldman
8/10/2022	$3.00	Buy → Underperform	BofA Securities
1/7/2022	$21.00	Neutral → Buy	BofA Securities
10/15/2021		Outperform	Cowen

SEC Form SC 13G/A filed by Singular Genomics Systems Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $OMIC

$OMIC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Singular Genomics Systems downgraded by UBS with a new price target

Singular Genomics Systems downgraded by Goldman with a new price target

Singular Genomics Systems downgraded by BofA Securities with a new price target

$OMIC Financials

Live finance-specific insights

Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

$OMIC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)

Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)

$OMIC SEC Filings

Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant

Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

SEC Form EFFECT filed by Singular Genomics Systems Inc.

$OMIC Press Releases

Fastest customizable press release news feed in the world

Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

Singular Genomics Announces Closing of Acquisition by Deerfield Management

Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share

$OMIC Leadership Updates

Live Leadership Updates

Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

$OMIC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

$OMIC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

SEC Form SC 13D filed by Singular Genomics Systems Inc.

Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

Recent Analyst Ratings for
$OMIC

$OMIC
Analyst Ratings

$OMIC
Financials

$OMIC
Insider Trading

$OMIC
SEC Filings

$OMIC
Press Releases

$OMIC
Leadership Updates

$OMIC
Insider Purchases

$OMIC
Large Ownership Changes